Broadridge Presents at Bernstein, Reiterates Growth Strategy; No New Catalysts Emerge

What happened

Broadridge Financial Solutions presented at the Bernstein Strategic Decisions Conference on May 27, 2026, reiterating its strategy to drive growth through the recent CQG acquisition and its resilient proxy processing business. Management emphasized the ~$1B sales pipeline and the conversion challenges that led to a downward revision in FY26 closed sales guidance. The company’s core ICS segment continues to show healthy equity position growth of 15% and retention near 98%, despite industry shifts toward internal proxy voting. However, the presentation did not introduce new quantitative milestones or specific timelines for CQG integration benefits, leaving the investment thesis reliant on upcoming fiscal 4Q26 results. The stock remains at $155, pricing in moderate skepticism with a 16.4x P/E multiple.

Implication

Long-term positive if CQG adds guided 3 points to growth and pipeline converts; but execution risk remains high. Wait for evidence before adding.

Thesis delta

The Bernstein presentation adds no incremental data to the existing thesis. The key milestones remain unchanged: first CQG contribution in fiscal 4Q26 and conversion of the $1B pipeline. No shift in view.